A peptide is a chain of amino acids held together by bonds that water, oxygen, heat and mechanical stress can all attack. Storage is the part of the workflow where most of the avoidable variance in a study comes from. A lot that arrived at 99.4% purity can drift well below that before it reaches the assay, and nothing on the Certificate of Analysis will warn you, because the certificate describes the vial on the day it was tested. This guide covers what actually governs stability for lyophilized powder and for solution, and what to write down.
Two states, two shelf lives
Lyophilized peptide and reconstituted peptide behave like different materials. Freeze-drying removes the water that most degradation chemistry needs. The remaining solid is a glassy matrix in which molecules barely move, so reaction rates fall by orders of magnitude. Add a diluent and the molecules are mobile again, the hydrolysis and deamidation pathways reopen, and the surface of the solution becomes a place where chains can unfold and stick together.
The practical consequence is simple. Treat the sealed powder as the stable form and the solution as a working stock with a short, dated life. Everything below follows from that split.
How long lyophilized powder lasts
Under the conditions most labs can achieve, a sealed lyophilized vial is the least demanding thing in the freezer. Typical handling in the published formulation literature and in routine practice looks like this.
| Condition | Lyophilized powder, sealed | Reconstituted solution |
|---|---|---|
| Room temperature, 20 to 25 °C | Tolerated for days in transit | Hours. Not a storage condition |
| Refrigerated, 2 to 8 °C | Months to a couple of years | The working condition, days to a few weeks by compound |
| Frozen, -20 °C | The common long-term choice | Acceptable if aliquoted first |
| Deep frozen, -80 °C | Longest hold, used for reference lots | Used for aliquots held across a long study |
Two details matter more than the number on the freezer. The vial must stay sealed, because lyophilized powder is hygroscopic and will pull moisture out of room air the moment the stopper is lifted. And the vial must be brought to room temperature before opening, or condensation forms on cold powder and starts the clock early. That step is easy to skip and it is the most common self-inflicted stability problem at the bench.
After reconstitution the clock speeds up
Once a compound such as BPC-157 is in solution, three things are true at the same time. The peptide is chemically reactive, the vial has been punctured, and the concentration is now a number your records have to carry. Standard practice is refrigeration at 2 to 8 °C, protection from light, and a discard date written on the vial at first puncture. Bacteriostatic diluent extends the usable window by suppressing microbial growth, which is the reason most multi-draw stocks use it. The choice between diluents is covered in bacteriostatic water versus sterile water, and the volume arithmetic in reconstituting lyophilized peptides.
Concentration itself affects stability. Very dilute solutions lose material to adsorption on glass and plastic. Very concentrated solutions favour aggregation. Mid-range stocks are the usual compromise.
How peptides actually break down
Three routes account for most of the loss.
- Oxidation. Methionine, cysteine and tryptophan residues react with dissolved oxygen and with trace metal ions that catalyse the reaction. The product is a peptide one or two mass units heavier, which mass spectrometry sees clearly and which may or may not retain activity. Headspace air in a part-used vial is the usual oxygen source.
- Deamidation and hydrolysis. Asparagine and glutamine residues lose their amide group in water, converting to aspartate or glutamate and sometimes forming an isomerised backbone. Rate depends strongly on pH and temperature. This is the pathway that makes refrigeration worthwhile for solutions.
- Aggregation. Partially unfolded chains associate with each other, first into soluble oligomers and then into visible particulate. Shaking, foaming, air-liquid interfaces and freeze-thaw all drive it. A solution that was clear and is now faintly hazy has aggregated, and centrifuging it does not restore the lost material.
Copper-carrying compounds add a fourth consideration. GHK-Cu is a peptide-metal complex, and the complex itself, not just the peptide chain, has to remain intact. Keep it away from strong chelators and from anything that would shift pH sharply.
Freeze-thaw and aliquoting
Freezing is not gentle. As ice forms, the remaining liquid becomes concentrated in both peptide and buffer salts, pH can shift by more than a unit in some buffer systems, and a large new ice-water interface appears. Each cycle through that transition costs a little material. Two or three cycles are survivable for most sequences. Ten are not.
The fix is aliquoting. Divide the reconstituted stock into single-experiment volumes in low-binding tubes, freeze them once, and thaw each aliquot once. The cost is a few minutes and some plasticware. The benefit is that experiment twelve sees the same material as experiment one.
Light, oxygen and summer shipping
Ultraviolet and short-wavelength visible light drive photo-oxidation of aromatic residues. Clear glass offers no protection, so amber vials, foil, or simply a closed drawer do the work. Ambient fluorescent light over a long weekend on an open bench is enough to matter for sensitive sequences.
Shipping in July raises a different question, asked most often about incretin compounds such as semaglutide. Lyophilized powder is robust to a few days of warm transit, and the formulation literature is consistent on that point. What is not acceptable is a package that sits in a hot vehicle for a week. Inspect the vial on arrival, confirm the cake is a dry white plug rather than a collapsed film, log the date and condition, and refrigerate or freeze promptly. A collapsed cake is not automatically failed material, but it is a reason to ask for the lot certificate.
What the logbook should record
- Compound, lot number and vial mass as labelled.
- Date received and the condition of the package and the cake on arrival.
- Storage location and temperature from receipt onward, including any gap.
- Date of reconstitution, diluent used, volume added, and resulting concentration.
- Number of aliquots made and where they are stored.
- Every freeze-thaw cycle, per aliquot.
- Date of first stopper puncture and the assigned discard date.
- Any observation of haze, colour, or particulate, with the date.
That list is short enough to keep on a card taped inside the freezer door, and it is what lets you explain an outlier six weeks later instead of guessing. The rest of the quality picture, including the tests a purity figure never covers, is in endotoxin, sterility and heavy-metal testing. Full product details for the compounds mentioned here are in the peptides collection.
Very short sequences are their own case. The bioregulator family, di- to tetrapeptides such as Epithalon and Pinealon, are introduced in bioregulator peptides explained, and the same storage principles apply to them.
Frequently asked questions
Does a reconstituted vial go bad on a fixed date?
No. Degradation is continuous, not a cliff, and the rate depends on the sequence, the diluent, the pH and the temperature. A discard date is a conservative convention, not a measurement. If the work is sensitive, re-test the stock rather than trusting the calendar.
Is -80 °C always better than -20 °C?
For long holds, generally yes, because molecular mobility falls further. For a stock that will be used within weeks, the difference is small and the extra handling and thaw time can cost more than it saves.
Can degraded peptide be recovered?
Not at the bench. Oxidation, deamidation and aggregation are chemical changes, not dissolution problems. Warming or vortexing a hazy solution redistributes the aggregate rather than reversing it.
References
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS, 2010, Pharmaceutical Research. Stability of protein pharmaceuticals: an update.
- Wang W, 1999, International Journal of Pharmaceutics. Instability, stabilization, and formulation of liquid protein pharmaceuticals.
- Wang W, 2000, International Journal of Pharmaceutics. Lyophilization and development of solid protein pharmaceuticals.
- Carpenter JF, Pikal MJ, Chang BS, Randolph TW, 1997, Pharmaceutical Research. Rational design of stable lyophilized protein formulations.
- Bhatnagar BS, Bogner RH, Pikal MJ, 2007, Pharmaceutical Development and Technology. Protein stability during freezing.
Research use only. This article describes laboratory handling of research reagents. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol.
